Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale.

Brünen S, Vincent PD, Baumann P, Hiemke C, Havemann-Reinecke U.

Ther Drug Monit. 2011 Oct;33(5):561-72. doi: 10.1097/FTD.0b013e31822fbf7c. Review.

PMID:
21912330
2.

Pharmacotherapy for Substance Use Disorders.

Klein JW.

Med Clin North Am. 2016 Jul;100(4):891-910. doi: 10.1016/j.mcna.2016.03.011. Epub 2016 Apr 20. Review.

PMID:
27235620
3.

Appropriateness of therapeutic drug monitoring for lithium.

Ratanajamit C, Soorapan S, Doang-ngern T, Waenwaisart W, Suwanchavalit L, Suwansiri S, Jantasaro S, Yanate I.

J Med Assoc Thai. 2006 Nov;89(11):1954-60.

PMID:
17205880
4.

[Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].

Marquet P.

Acta Clin Belg. 1999;53 Suppl 1:2-12. Review. French.

PMID:
10216973
5.

The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.

Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G; Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie.

Pharmacopsychiatry. 2004 Nov;37(6):243-65. Review.

PMID:
15551191
6.

AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G.

Pharmacopsychiatry. 2011 Sep;44(6):195-235. Review.

PMID:
22053351
7.

[Pharmacological treatment of substance dependence from a neuroscientific perspective (I): opiates and cocaine].

Haro G, Cervera G, Martínez-Raga J, Pérez-Gálvez B, Fernández-Garcés M, Sanjuan J.

Actas Esp Psiquiatr. 2003 Jul-Aug;31(4):205-19. Review. Spanish.

PMID:
12838444
8.

Therapeutic drug monitoring of clozapine and relapse--a retrospective study of routine clinical data.

Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B, Meyer FP.

Int J Clin Pharmacol Ther. 2003 Jan;41(1):3-13.

PMID:
12564740
9.

[Therapeutic drug monitoring (TDM) of psychotropic drugs: a consensus guideline of the AGNP-TDM group].

Baumann P, Hiemke C, Ulrich S, Eckermann G, Kuss HL, Laux G, Müller-Oerlingenhausen B, Rao ML, Riederer P, Zernig G; AGNP-TDM; Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) - Therapeutic Drug Monitoring (TDM).

Rev Med Suisse. 2006 May 24;2(67):1413-8, 1420-2, 1424-6. Review. French.

PMID:
16786958
10.

Effect of pharmacist participation in the health care team on therapeutic drug monitoring utilization for antiepileptic drugs.

Ratanajamit C, Kaewpibal P, Setthawacharavanich S, Faroongsarng D.

J Med Assoc Thai. 2009 Nov;92(11):1500-7.

PMID:
19938743
11.

Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence.

Ulrich S, Hiemke C, Laux G, Müller-Oerlinghausen B, Havemann-Reinecke U, Riederer P, Zernig G, Baumann P; TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP).

Pharmacopsychiatry. 2007 May;40(3):121-7.

PMID:
17541888
12.

Cost-effectiveness of therapeutic drug monitoring: a systematic review.

Touw DJ, Neef C, Thomson AH, Vinks AA; Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.

Ther Drug Monit. 2005 Feb;27(1):10-7. Review.

PMID:
15665740
13.

Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring.

Takada M, Goto T, Kotake T, Saito M, Kawato N, Nakai M, Gunji T, Shibakawa M.

J Clin Pharm Ther. 2005 Feb;30(1):5-12.

PMID:
15658999
14.

Therapeutic drug monitoring of immunosuppressant drugs in clinical practice.

Kahan BD, Keown P, Levy GA, Johnston A.

Clin Ther. 2002 Mar;24(3):330-50; discussion 329. Review. Erratum in: Clin Ther. 2002 Jul;24(7):1223..

PMID:
11952020
15.

Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?

Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C.

Pharmacopsychiatry. 2003 May;36(3):98-104.

PMID:
12806567
16.

French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs.

Rougemont M, Ulrich S, Hiemke C, Corruble E, Baumann P.

Fundam Clin Pharmacol. 2010 Jun;24(3):377-84. doi: 10.1111/j.1472-8206.2010.00815.x. Epub 2010 Feb 22.

PMID:
20199581
17.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
18.
19.

Clinical benefit of interventions driven by therapeutic drug monitoring.

Rendón A, Núñez M, Jiménez-Nácher I, González de Requena D, González-Lahoz J, Soriano V.

HIV Med. 2005 Sep;6(5):360-5.

20.

The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection.

Pretorius E, Klinker H, Rosenkranz B.

Ther Drug Monit. 2011 Jun;33(3):265-74. doi: 10.1097/FTD.0b013e31821b42d1. Review.

PMID:
21566505

Supplemental Content

Support Center